Estrogen and postmenopausal estrogen/progestin therapy: Effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 79, Issue 1, 1998, Pages 75-82

  Mikkola, Tomi ^a   Viinikka, Lasse ^a   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Estrogen; Hormone replacement therapy; Menopause; Vasoactive agents

Indexed keywords

ENDOTHELIN 1; ESTROGEN; GESTAGEN; NITRIC OXIDE; PROSTACYCLIN;

ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; ESTROGEN DEFICIENCY; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0031831720     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00050-5     Document Type: Article

References (100)

1. Lerner DJ, Kannel WB Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 111:1986;383-390.
2. Kannel WB, Hjortland MC, McNamara PM, Gordon T Menopause and risk of cardiovascular disease. The Framingham study. Ann Intern Med. 85:1976;447-452.
3. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans MJC, Banga JD Age at menopause as a risk factor for cardiovascular mortality. Lancet. 347:1996;714-718.
4. Bush TL, Barrett-Connor E, Cowan LDet al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 75:1987;1102-1109.
5. Henderson BE, Paganini-Hill A, Ross RK Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 159:1988;312-317.
6. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J. 117:1989;1209-1214.
7. Hunt K, Vessey M, McPherson K Mortality in a cohort of long-term users of hormone replacement therapy: an update analysis. Br J Obstet Gynaecol. 97:1990;1080-1086.
8. Sullivan JM, Zwaag RV, Hughes JPet al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 150:1990;2557-2562.
9. Stampfer MJ, Colditz GA, Willett WCet al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 325:1991;756-762.
10. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 164:1991;489-494.
11. Falkeborn M, Persson I, Adami H-Oet al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 99:1992;821-828.
12. Grodstein F, Stampfer MJ, Manson JEet al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
13. Grodstein F, Stampfer MJ, Colditz GAet al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
14. Lobo RA, Speroff L International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril. 62(Suppl 2):1994;176S-179S.
15. Hammond CB Menopause and hormone replacement therapy: an overview. Obstet Gynecol. 87:1996;2S-15S.
16. Tikkanen MJ, Kuusi T, Vartiainen E, Nikkilä EA Treatment of post-menopausal hypercholesterolaemia with estradiol. Acta Obstet Gynecol Scand. 88:1979;83-88.
17. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1991;1196-1204.
18. Darling GM, Johns JA, McCloud PI, Davis SR Estrogen and progestin compared with simvastin for hypercholesterolemia in postmenopausal women. N Engl J Med. 337:1997;595-601.
19. Grady D, Rubin SM, Petitti DBet al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
20. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 342:1993;133-136.
21. Mendelsohn ME, Karas RH Estrogen and the blood vessel wall. Curr Opin Cardiol. 9:1994;619-626.
22. Vane JR, Ånggård EE, Botting RM Regulatory functions of the vascular endothelium. N Engl J Med. 323:1990;27-36.
23. Shimokawa H, Takeshita A Endothelium-dependent regulation of the cardiovascular system. Intern Med. 34:1995;939-946.
24. 2 , and prostacyclin. Pharmacol Rev. 30:1979;293-331.
25. Weksler BB, Ley CW, Jaffe EA Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A23187. J Clin Invest. 62:1978;923-930.
26. Endo H, Akahoshi T, Kashiwazaki S Additive effects of IL-1 and TNF on induction of prostacyclin synthesis in human vascular endothelial cells. Biochem Biophys Res Commun. 156:1988;1007-1014.
27. Ristimäki A, Ylikorkala O, Viinikka L Effect of growth factors on human vascular endothelial cell prostacyclin production. Arteriosclerosis. 10:1990;653-657.
28. 2 reduces activation of human arterial smooth muscle cells in-vivo. Prostaglandins. 33:1987;915-918.
29. Ross R The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
30. Pomerantz KB, Nicholson AC, Hajjar DP Signal transduction in atherosclerosis: second messengers and regulation of cellular cholesterol trafficking. Adv Exp Med Biol. 369:1995;49-64.
31. Furchgott RF, Zawadzki JV The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
32. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 84:1987;9265-9269.
33. Palmer RMJ, Ferrige AG, Moncada S Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
34. Radomski MW, Palmer RMJ, Moncada S The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 92:1987;639-646.
35. Tsao PS, Lewis NP, Alpert S, Cooke JP Exposure to shear stress alters endothelial adhesiveness. Role of nitric oxide. Circulation. 92:1995;3513-3519.
36. Yanagisawa M, Kurihara H, Kimura Set al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
37. Masaki T Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocrine Rev. 14:1993;256-268.
38. Wagner OF, Christ G, Wojta Jet al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 267:1992;16066-16068.
39. Weitzberg E, Ahlborg G, Lundberg JM Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol. 13:1993;653-662.
40. Miyauchi T, Yanagisawa M, Tomizawa Tet al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 2:1989;53-54.
41. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 325:1991;997-1001.
42. Giaid A, Yanagisawa M, Langleben Det al. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739.
43. Wei C-M, Lerman A, Rodeheffer RJet al. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
44. Taylor RN, Varma M, Teng NNH, Roberts JM Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 71:1990;1675-1677.
45. Benigni A, Orisio S, Gaspari F, Frusca T, Amuso G, Remuzzi G Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br J Obstet Gynaecol. 99:1992;798-802.
46. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol. 258:1990;C408-415.
47. Seillan C, Ody C, Russo-Marie F, Duval D Differential effects of sex steroids on prostaglandin synthesis by male and female cultured piglet endothelial cells. Prostaglandins. 26:1983;3-12.
48. 2 release. Prostaglandins Leukotrienes Essent Fatty Acids. 54:1996;403-409.
49. Mäkilä U-M, Wahlberg L, Viinikka L, Ylikorkala O Regulation of prostacyclin and thromboxane production by human umbilical vessels: the effect of estradiol and progesterone in a superfusion model. Prostaglandins Leukotrienes Med. 8:1982;115-124.
50. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O 17β-Estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab. 80:1995;1832-1836.
51. 2 and NO in endothelial cells. Maturitas. 25:1996;141-147.
52. Ristimäki A, Renkonen R, Saijonmaa O, Ylikorkala O, Viinikka L Human serum stimulate endothelin-1 synthesis more potently than prostacyclin production by cultured vascular endothelial cells. Life Sci. 49:1991;603-609.
53. Mikkola T, Ristimäki A, Viinikka L, Ylikorkala O Human serum, plasma, and platelets stimulate prostacyclin and endothelin-1 synthesis in human vascular endothelial cells. Life Sci. 53:1993;283-289.
54. Mück AO, Seeger H, Korte K, Dartsch PC, Lippert TH Natural and synthetic estrogens and prostacyclin production in human endothelial cells from umbilical cord and leg veins. Prostaglandins. 45:1993;517-525.
55. Corvazier E, Dupuy E, Dosne AM, Maclouf J Minimal effect of estrogens on endothelial cell growth and production of prostacyclin. Thromb Res. 34:1984;303-310.
56. Mikkola T, Ranta V, Orpana A, Viinikka L, Ylikorkala O Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells. Fertil Steril. 66:1996;389-393.
57. Foidart JM, Dombrowitz N, de Ligniéres B. Urinary excretion of prostacyclin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel®) or conjugated estrogens (Premarin®). In: Dusitsin N, Notelovitz M, editors. Physiological hormone replacement therapy. Carnforth, UK: Parthenon, 1991.
58. Mück AO, Seeger H, Wiesner J, Korte K, Lippert TH Urinary prostanoids in postmenopausal women after transdermal and oral oestrogen. J Obstet Gynaecol. 14:1994;341-345.
59. 2 . Obstet Gynecol. 89:1997;104-107.
60. Ylikorkala O, Hirvonen E, Saure A, Viinikka L Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. Prostaglandins. 39:1990;33-37.
61. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 360:1995;291-293.
62. Hayashi T, Yamada K, Esaki Tet al. Estrogen increases endothelial nitric oxide by a receptor mediated system. Biochem Biophys Res Commun. 214:1995;847-855.
63. Schray-Utz B, Zeiher AM, Busse R Expression of constitutive NO synthase in cultured endothelial cells is enhanced by 17β-estradiol. Circulation. 88:1993;1-80.
64. Sayegh HS, Ohara Y, Navas JP, Peterson TE, Dockery S, Harrison DG Endothelial nitric oxide synthase regulation by estrogens. Circulation. 88:1993;1-80.
65. Gisclard V, Miller VM, Vanhoutte PM Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 244:1988;19-22.
66. Williams SP, Shackelford DP, Iams SG, Mustafa SJ Endothelium-dependent relaxation in estrogen-treated spontaneously hypertensive rats. Eur J Pharmacol. 145:1988;205-207.
67. Vedernikov YP, Liao QP, Jain V, Saade GR, Chwalisz K, Garfield RE Effect of chronic treatment with 17beta-estradiol and progesterone on endothelium-dependent and endothelium-independent relaxation in isolated aortic rings from ovariectomized rats. Am J Obstet Gynecol. 176:1997;603-608.
68. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:1994;786-791.
69. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
70. Volterrani M, Rosano G, Coats A, Beale C, Collins P Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med. 99:1995;119-122.
71. Cicinelli E, Ignarro LJ, Lograno M, Matteo G, Falco N, Schonauer LM Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 67:1997;63-66.
72. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab. 82:1997;388-394.
73. Williams JK, Adams MR, Herrington DM, Clarkson TB Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 20:1992;452-457.
74. Ylikorkala O, Orpana A, Puolakka J, Pyörälä T, Viinikka L Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 80:1995;3384-3387.
75. Wilcox JG, Hatch IE, Gentzschein E, Stanczyk FZ, Lobo RA Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril. 67:1997;273-277.
76. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 118:1993;429-432.
77. Creatsas GC, Malamitsi-Puchner AB, Hassan EA, Economou EB, Aravantinos DI Endothelin plasma levels in primary amenorrheic adolescents before and after estrogen treatment. J Soc Gynecol Invest. 3:1996;350-353.
78. White MM, Zamudio S, Stevens Tet al. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocrine Rev. 16:1995;739-751.
79. Horwitz KB, Horwitz LD Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest. 69:1982;750-758.
80. Lin AL, Shain SA Estrogen-mediated cytoplasmic and nuclear distribution of rat cardiovascular estrogen receptors. Arteriosclerosis. 5:1985;668-677.
81. Leiberman JR, van Vroonhoven CCJ, Beckmann I, van der Kwast TH, Wallenburg HCS Uterine artery estrogen receptors in the nonpregnant and pregnant guinea pig. Am J Obstet Gynecol. 163:1990;1685-1688.
82. Lantta M, Kärkkäinen J, Lehtovirta P Progesterone and estradiol receptors in the cytosol of the human uterine artery. Am J Obstet Gynecol. 147:1983;627-633.
83. Bergqvist A, Bergqvist D, Fernö M Estrogen and progesterone receptors in vessel walls. Biochemical and immunochemical assays. Acta Obstet Gynecol Scand. 72:1993;10-16.
84. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 89:1994;1501-1510.
85. Orimo A, Inoue S, Ikegami Aet al. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun. 195:1993;730-736.
86. Colburn P, Buonassisi V Estrogen-binding sites in endothelial cell cultures. Science. 201:1978;817-819.
87. Buonassisi V, Venter JC Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci USA. 73:1976;1612-1616.
88. Nakhla AM, Mather JP, Jänne OA, Bardin CW Estrogen and androgen receptors in sertoli, leydig, myoid, and epithelial cells: effects of time in culture and cell density. Endocrinology. 115:1984;121-128.
89. Press MF, Nousek-Goebl N, King WJ, Herbst AL, Greene GL Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest. 51:1984;495-503.
90. Perrot-Applanat M, Deng M, Fernandez H, Lelaidier C, Meduri G, Bouchard P Immunohistochemical localization of estradiol and receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. J Clin Endocrinol Metab. 78:1994;216-224.
91. Venkov CD, Rankin AB, Vaughan DE Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation. 94:1996;727-733.
92. Kim-Schulze S, McGowan KA, Hubchak SCet al. Expression of an estrogen receptor by human coronary and umbilical vein endothelial cells. Circulation. 94:1996;1402-1407.
93. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation. 95:1997;1505-1514.
94. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:1996;5925-5930.
95. Mosselman S, Polman J, Dijkema R ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
96. Iafrati MD, Karas RH, Aronovitz Met al. Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nature Med. 3:1997;545-548.
97. Ramirez VD How do steroids act? Lancet. 347:1996;630-631.
98. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol. 266:1994;C975-C980.
99. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz J-L A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 131:1992;1305-1312.
100. Pappas TC, Gametchu B, Watson CS Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 9:1995;404-410.